Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Barreiro

Showing results (111-120 of 220) with videos related to

Pageof 22
Sort By:
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|August 25, 2015
Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis CPablo Barreiro, Pablo Labarga, José V Fernandez-Montero, et al.
Antiviral Therapy|February 17, 2007
Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patientsPablo Barreiro, Pablo Labarga, Luz Martín-Carbonero, et al.
The Journal of Infectious Diseases|March 16, 2007
Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitisVincent Soriano, Pablo Barreiro, Luz Martín-Carbonero, et al.
Antiviral Therapy|February 19, 2016
High serum HCV RNA in chronic hepatitis C patients coinfected with HIV despite successful antiretroviral therapyPablo Barreiro, Pablo Labarga, Carmen de Mendoza, et al.
Expert Opinion on Pharmacotherapy|April 30, 2013
Hepatitis C therapy with HCV NS5B polymerase inhibitorsVincent Soriano, Eugenia Vispo, Carmen de Mendoza, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 16, 2005
Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1Sonia Rodríguez Nóvoa, Pablo Barreiro, Ana Rendón, et al.
International Journal of Antimicrobial Agents|November 30, 2002
Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitorsPablo Barreiro, Nuria Camino, Carmen de Mendoza, et al.
AIDS (London, England)|December 7, 2006
Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemiaSonia Rodríguez-Nóvoa, Luz Martín-Carbonero, Pablo Barreiro, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 11, 2017
Drug interactions in HIV-infected patients treated for hepatitis CVicente Soriano, Pablo Labarga, José V Fernandez-Montero, et al.
HIV Clinical Trials|May 29, 2002
SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individualsMarina Núñez, Vincent Soriano, Luz Martín-Carbonero, et al.
Pageof 22

Showing results (111-120 of 220) with videos related to

Sort By:
Pageof 22
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|August 25, 2015
Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis CPablo Barreiro, Pablo Labarga, José V Fernandez-Montero, et al.
Antiviral Therapy|February 17, 2007
Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patientsPablo Barreiro, Pablo Labarga, Luz Martín-Carbonero, et al.
The Journal of Infectious Diseases|March 16, 2007
Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitisVincent Soriano, Pablo Barreiro, Luz Martín-Carbonero, et al.
Antiviral Therapy|February 19, 2016
High serum HCV RNA in chronic hepatitis C patients coinfected with HIV despite successful antiretroviral therapyPablo Barreiro, Pablo Labarga, Carmen de Mendoza, et al.
Expert Opinion on Pharmacotherapy|April 30, 2013
Hepatitis C therapy with HCV NS5B polymerase inhibitorsVincent Soriano, Eugenia Vispo, Carmen de Mendoza, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 16, 2005
Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1Sonia Rodríguez Nóvoa, Pablo Barreiro, Ana Rendón, et al.
International Journal of Antimicrobial Agents|November 30, 2002
Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitorsPablo Barreiro, Nuria Camino, Carmen de Mendoza, et al.
AIDS (London, England)|December 7, 2006
Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemiaSonia Rodríguez-Nóvoa, Luz Martín-Carbonero, Pablo Barreiro, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 11, 2017
Drug interactions in HIV-infected patients treated for hepatitis CVicente Soriano, Pablo Labarga, José V Fernandez-Montero, et al.
HIV Clinical Trials|May 29, 2002
SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individualsMarina Núñez, Vincent Soriano, Luz Martín-Carbonero, et al.
Pageof 22